绝代双骄

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

重口味

A | 凯文教育：本次计提资产减值准备对半年度净利润影响为-223.2万元每经AI快讯，凯文教育（SZ002659，收盘价：4.57元）8月25日晚间发布公告称，本次计提资产减值准备对2026年半年度所有者权益影响为-223.2万元、对净利润影响为-223.2万元。每经头条（nbdtoutiao）——冲刺“全球视频大模型第一股”！每经独家透视可灵AI：客户都在哪？运营状况如何？（记者曾健辉）免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。 (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。据此操作，风险自担。每日经济新闻。

Current article:http://www.bianhajieleigoukusunmen.pics/news/20260826_4445.pptx

Published on:00:47:38